Aarhus bio-startup acquired by Americans: “To expand our shared vision of developing next generation solutions”

This post is also available in: Danish

Biological antibodies play a central role in modern drug development, and the need for advanced technological tools that can adapt to new antibody formats and laboratory techniques is growing. To meet this need, the American company Benchling has acquired the Danish startup PipeBio, which specializes in cloud-based bioinformatics for biologics research.

Read also: With one connector, Startup of the Week will ensure better biopsies: “We see great economic potential for patients, hospitals and society as a whole” – TechSavvy

Founded in 2020 by Jannick Bendtsen and Owen Bodley, PipeBio has developed a cloud platform that enables researchers to screen large libraries of antibodies and analyze millions of sequences. The technology is designed to help researchers visualize data and identify the best candidates for further development. This technology complements Benchling’s existing software and makes it possible to offer a complete solution that covers the entire process from early screening to the production of clinical candidates.

“We are excited to join Benchling and expand our shared vision to develop next-generation solutions for biologics research and development,” PipeBio writes on their website.

Close partnership behind the acquisition

The acquisition of PipeBio comes after three years of collaboration between the two companies, where PipeBio had already integrated their platform with Benchling through a developer program. This collaboration allowed the two companies to understand the mutual benefits of an integrated solution and paved the way for the acquisition.

Read also: Leading platform acquires Aarhus startup to boost AI-powered customer service in Europe – TechSavvy

Although PipeBio is now part of Benchling, the company will continue its daily operations as before, but with access to the resources and capabilities Benchling offers. The acquisition is part of Benchling’s strategy to create an open platform that supports integration with other biotechnology products and solutions.

With the acquisition of PipeBio, Benchling will strengthen its position as a major player in the development of software for biological research and drug development.